Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II clinical trial of MT027 for the treatment of recurrent glioblastoma (rGBM)

Next Previous
Trial Profile

A Phase II clinical trial of MT027 for the treatment of recurrent glioblastoma (rGBM)

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 12 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MT 027 (Primary)
  • Indications Glioblastoma
  • Focus Therapeutic Use

Most Recent Events

  • 12 Jan 2026 New trial record
  • 21 Dec 2025 According to a T-MAXIMUM Pharmaceutical media release, MT027, has received IND Clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase II clinical trial for the treatment of recurrent glioblastoma (rGBM).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top